Ping Zou

Jun 24, 2024 | onlinelibrary.wiley.com | Jing An |Shanxi Academy |Jie Zhao |Ping Zou

1 INTRODUCTION Multiple myeloma (MM) is a common malignant tumor in clinical practice.1 Over recent decades, the survival of patients with MM has significantly improved with the widespread use of anti-MM agents.2 Chimeric antigen receptor (CAR) T-cell therapy has also provided a new regimen for the treatment of relapsed refractory MM (RRMM), showing substantial efficacy with controllable adverse reactions.3-5 The US Food and Drug Administration has approved the CAR-T cell products...